DBV TechnologiesDBVT -4.17%31 EV-to-EBITDA is -4.41 as of Jul. 09, 2026. GuruFocus rates DBVT with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 392 Biotechnology companies, DBV Technologies ranks worse than 255101.79% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, DBV Technologies's enterprise value is $706.99 Mil.
DBV Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-160.18 Mil. Therefore, DBV Technologies's EV-to-EBITDA for today is -4.41.
The historical rank and industry rank for DBV Technologies's EV-to-EBITDA or its related term are showing as below:
DBVT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.77 Med: 0 Max: 0
Current: -4.41
DBVT's EV-to-EBITDA is ranked worse than 100% of 392
companies
in the Biotechnology industry
Industry Median: 12.965
vs DBVT: -4.41
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
DBV Technologies's PE Ratio (TTM) for today is calculated as:
DBV Technologies's share price for today is $16.08.
DBV Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.450.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for DBV Technologies's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, DBV Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DBV Technologies EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DBV Technologies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where DBV Technologies's EV-to-EBITDA falls into.
DBV Technologies's current Enterprise Value is $706.99 Mil.
DBV Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-160.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DBV Technologies (DBVT) has a EV-to-EBITDA of -4.41 as of Jul. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on DBV Technologies. According to the industry distribution chart, DBV Technologies ranks #999999 out of 392 companies in the Biotechnology industry.
Is DBV Technologies' EV-to-EBITDA too high?
DBV Technologies' current EV-to-EBITDA is -4.41. Based on the distribution chart, DBV Technologies ranks #999999 out of 392 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, DBV Technologies has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DBV Technologies' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DBV Technologies ranks #999999 out of 392 companies for EV-to-EBITDA. This places DBV Technologies in the lower half of its industry. The industry median EV-to-EBITDA is 12.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.97, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on DBV Technologies. For the Biotechnology industry, the median EV-to-EBITDA is 12.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DBV Technologies's current EV-to-EBITDA is -4.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DBV Technologies stock overvalued right now?
DBV Technologies (DBVT) has a current EV-to-EBITDA of -4.41. The current EV-to-EBITDA is -4.41. DBV Technologies' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For DBV Technologies (DBVT), the current EV-to-EBITDA is -4.41 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
31GF Score
Get the complete analysis for DBVT
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DBVT has been successfully added to your 
